G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Wednesday, AnalystRatings.com reports. They currently have a $72.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 93.44% from the company’s current price.

The analysts wrote, “We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48.””

GTHX has been the topic of a number of other reports. JPMorgan Chase & Co. upgraded G1 Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $38.00 to $45.00 in a report on Thursday, August 8th. BidaskClub upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. Zacks Investment Research downgraded G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Finally, ValuEngine upgraded G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. G1 Therapeutics has an average rating of “Buy” and a consensus target price of $56.67.

GTHX traded down $2.55 during trading on Wednesday, hitting $37.22. 13,901 shares of the stock were exchanged, compared to its average volume of 342,955. The firm has a 50 day simple moving average of $32.42 and a 200 day simple moving average of $23.92. The firm has a market cap of $1.50 billion, a price-to-earnings ratio of -15.00 and a beta of 2.35. G1 Therapeutics has a 1 year low of $13.87 and a 1 year high of $69.35.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.09). As a group, equities analysts forecast that G1 Therapeutics will post -3.26 EPS for the current year.

Several large investors have recently made changes to their positions in GTHX. BlackRock Inc. increased its holdings in shares of G1 Therapeutics by 27.4% in the 2nd quarter. BlackRock Inc. now owns 2,468,415 shares of the company’s stock valued at $75,681,000 after acquiring an additional 530,999 shares during the period. JPMorgan Chase & Co. grew its stake in G1 Therapeutics by 27.8% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,429,138 shares of the company’s stock worth $44,446,000 after buying an additional 310,614 shares during the last quarter. Tang Capital Management LLC purchased a new position in G1 Therapeutics during the 2nd quarter worth $6,132,000. Nuveen Asset Management LLC purchased a new position in G1 Therapeutics during the 2nd quarter worth $3,505,000. Finally, UBS Asset Management Americas Inc. grew its stake in G1 Therapeutics by 83.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 249,282 shares of the company’s stock worth $7,643,000 after buying an additional 113,294 shares during the last quarter. Institutional investors and hedge funds own 74.93% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Recommended Story: How is inflation measured?

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.